KDR and renal cell carcinoma: Axitinib is an inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRα, and PDGFRβ, approved by the U.S. FDA in 2012 for the second-line therapy for advanced renal cell carcinoma (RCC) (124–127).